Gompertz et al. [57] and Gronke et al.[58] showed a small decrease in sputum MPO level in the patients treated with LTB4 receptor antagonists on sputum MPO levels in COPD patients. The gene discussed is MPO; the disease is chronic obstructive pulmonary disease.